Unlocking the Potential of Carboxylesterase 4A (ISO Form 1) as a Drug Target and Biomarker

Target Name: CES4A

NCBI ID: G283848

CES4A

Unlocking the Potential of Carboxylesterase 4A (ISO Form 1) as a Drug Target and Biomarker

Carboxylesterase 4A (ISO Form 1) is an enzyme located in the cytoplasm of eukaryotic cells that plays a crucial role in the metabolism of carboxylic acids. It is one of the six known isoforms of the enzyme carboxylesterase and is responsible for the majority of the activity of this enzyme in the cell. carboxylesterase 4a is expressed in most tissues and is involved in the catenylation of longchain fatty acids with CoA, resulting in the formation of fatty acids esters.

Recent studies have identified CES4A as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. In this article, we will explore the recent findings on CES4A and its potential as a drug target and biomarker.

CES4A as a Drug Target

CES4A has been identified as a potential drug target due to its involvement in various cellular processes that are crucial for human health. One of the main reasons for its potential as a drug target is its involvement in the metabolism of fatty acids, which are essential for brain and muscle function. CES4A is known to catalyze the conversion of longchain fatty acids to their esters, which are crucial for the synthesis of fatty acids esters, including those that are essential for brain and muscle function.

Studies have shown that alterations in the levels of CES4A have been associated with various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. For example, studies have shown that individuals with certain genetic variations in the CES4A gene are at an increased risk of developing cancer. Additionally, alterations in the levels of CES4A have been linked to the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

CES4A as a Biomarker

CES4A has also been identified as a potential biomarker for various diseases. The ability to measure the levels of CES4A in a patient's body fluids, such as blood or urine, can be used to monitor the effectiveness of a treatment and to predict the outcomes of a disease. For example, measuring the levels of CES4A in urine has been used as a biomarker for various diseases, including cancer and neurodegenerative diseases.

Studies have shown that individuals with certain genetic variations in the CES4A gene are at an increased risk of developing certain diseases, including cancer. Additionally, changes in the levels of CES4A have been linked to the development of various diseases, including neurodegenerative diseases. These findings suggest that CES4A may be a useful biomarker for the diagnosis and treatment of these diseases.

Conclusion

In conclusion, CES4A is an enzyme that plays a crucial role in the metabolism of carboxylic acids and has been identified as a potential drug target and biomarker for various diseases. Its involvement in the synthesis of fatty acids esters and its association with various diseases make it an attractive target for drug development. Further research is needed to fully understand the role of CES4A as a drug target and biomarker and to develop effective treatments for the various diseases associated with its alterations.

Protein Name: Carboxylesterase 4A

Functions: Probable carboxylesterase

The "CES4A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CES4A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets